These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 15713902

  • 1. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
    Chen AY, Shih SJ, Garriques LN, Rothenberg ML, Hsiao M, Curran DP.
    Mol Cancer Ther; 2005 Feb; 4(2):317-24. PubMed ID: 15713902
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
    Urasaki Y, Takebayashi Y, Pommier Y.
    Cancer Res; 2000 Dec 01; 60(23):6577-80. PubMed ID: 11118036
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity.
    Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S, Howe JN, Bingcang A, Latus LJ, Burke TG.
    J Control Release; 2001 Jul 06; 74(1-3):325-33. PubMed ID: 11489514
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. p53 and p21 are major cellular determinants for DNA topoisomerase I-mediated radiation sensitization in mammalian cells.
    Chen AY, Scruggs PB, Geng L, Rothenberg ML, Hallahan DE.
    Ann N Y Acad Sci; 2000 Jul 06; 922():298-300. PubMed ID: 11193905
    [No Abstract] [Full Text] [Related]

  • 9. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
    Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y.
    Cancer Res; 2001 Jan 15; 61(2):504-8. PubMed ID: 11212241
    [Abstract] [Full Text] [Related]

  • 10. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
    Yanase K, Sugimoto Y, Tsukahara S, Oh-Hara T, Andoh T, Tsuruo T.
    Jpn J Cancer Res; 2000 May 15; 91(5):551-9. PubMed ID: 10835501
    [Abstract] [Full Text] [Related]

  • 11. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
    Pondarré C, Strumberg D, Fujimori A, Torres-León R, Pommier Y.
    Nucleic Acids Res; 1997 Oct 15; 25(20):4111-6. PubMed ID: 9321666
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
    Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, Pommier Y.
    Cancer Res; 2001 Mar 01; 61(5):1964-9. PubMed ID: 11280753
    [Abstract] [Full Text] [Related]

  • 14. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
    Tanizawa A, Pommier Y.
    Cancer Res; 1992 Apr 01; 52(7):1848-54. PubMed ID: 1312902
    [Abstract] [Full Text] [Related]

  • 15. The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
    Bence AK, Mattingly CA, Burke TG, Adams VR.
    Cancer Chemother Pharmacol; 2004 Oct 01; 54(4):354-60. PubMed ID: 15197485
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.
    Chen AY, Chou R, Shih SJ, Lau D, Gandara D.
    Crit Rev Oncol Hematol; 2004 May 01; 50(2):111-9. PubMed ID: 15157660
    [Abstract] [Full Text] [Related]

  • 17. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C, Simonsen AK, Andersen MB, Petersen KW, Kristoffersen EL, Algreen L, Hansen NY, Andersen AB, Jakobsen AK, Stougaard M, Gromov P, Knudsen BR, Gromova I.
    BMC Cancer; 2019 Nov 29; 19(1):1158. PubMed ID: 31783818
    [Abstract] [Full Text] [Related]

  • 18. Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.
    Scaldaferro S, Tinelli S, Borgnetto ME, Azzini A, Capranico G.
    Chem Biol; 2001 Sep 29; 8(9):871-81. PubMed ID: 11564555
    [Abstract] [Full Text] [Related]

  • 19. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y, Weinstein JN, Kohn KW, Shi LM, Pommier Y.
    J Med Chem; 1998 Jun 18; 41(13):2216-26. PubMed ID: 9632354
    [Abstract] [Full Text] [Related]

  • 20. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
    Tomicic MT, Kaina B.
    Biochim Biophys Acta; 2013 Jan 18; 1835(1):11-27. PubMed ID: 23006513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.